Skip to main content
Erschienen in: World Journal of Surgery 4/2021

25.01.2021 | Original Scientific Report

Changes in the Role and Mode of Liver Resection for Hepatocellular Carcinoma Over 20 Years: A Single-Center Analysis

verfasst von: Susumu Eguchi, Masaaki Hidaka, Tota Kugiyama, Akihiko Soyama, Takanobu Hara, Kantoku Nagakawa, Tomohiko Adachi, Takayuki Tanaka, Tomoko Yoshimoto, Takashi Hamada, Hajime Matsushima, Sinichiro Ito, Kengo Kanetaka

Erschienen in: World Journal of Surgery | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Introduction

The aim of this study was to analyze changes in characteristics of HCC and the modes of LR over 20 years in order to show the impact of those changes in the outcome of LR. In addition, BCLC staging was used to assess the limitations of this classification system and changes over the decade.

Patients and methods

In our department, 500 liver resections (LR) were performed for hepatocellular carcinoma (HCC) over the 20 years between January 2000 and February 2020. The 208 cases performed through 2009 were designated as Era 1, and the 292 cases between 2010 and February 2020 were termed Era 2. We analyzed changes in the characteristics of HCC and mode of LR (Study 1), and final outcomes of LR are shown according to the BCLC staging classifications and eras using data from the 5 years after LR (Study 2).

Results

In Era 1, the mean age of the patients was 68, while in Era 2 the mean age was 71, which was significantly older than the patients in Era 1. HCC that developed from non-B, non-C liver cirrhosis was significantly increased in Era 2 (45%) as compared to that in Era 1 (34%). Laboratory data were all comparable between the eras in patients undergoing LR for HCC. The size and numbers of the HCC as well as tumor markers were similar between the eras. As to the mode of LR, although the extent of LR was similar between the eras, the laparoscopic method was significantly increased in Era 2. Blood loss was significantly lower in Era 2 (mean 519 g) than in Era 1 (1,085 g). Patient survival and recurrence-free survival (RFS) were similar between the two eras, while RFS at 5 years after LR was better in Era 2. Even in the BCLC A category, only patients with a single HCC less than 5 cm showed best results, while patients with HCC within the rest of BCLC A and BCLC B showed a dismal outcome. There was no difference in OS and RFS between the eras after stratification by BCLC.

Conclusion

There are conspicuous changes in the baseline characteristics and mode of LR over 20 years, which should be taken into account for patient care and informed consent for patients undergoing LR going forward.
Literatur
1.
Zurück zum Zitat Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T et al (2019) Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 8(3):1054–1065CrossRef Tarao K, Nozaki A, Ikeda T, Sato A, Komatsu H, Komatsu T et al (2019) Real impact of liver cirrhosis on the development of hepatocellular carcinoma in various liver diseases-meta-analytic assessment. Cancer Med 8(3):1054–1065CrossRef
2.
Zurück zum Zitat Nakano M, Koga H, Ide T, Kuromatsu R, HashimotoS YH, Seike M et al (2019) Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. Cancer Med 8(5):2646–2653CrossRef Nakano M, Koga H, Ide T, Kuromatsu R, HashimotoS YH, Seike M et al (2019) Predictors of hepatocellular carcinoma recurrence associated with the use of direct-acting antiviral agent therapy for hepatitis C virus after curative treatment: a prospective multicenter cohort study. Cancer Med 8(5):2646–2653CrossRef
3.
Zurück zum Zitat Tanaka J, Akita T, Ko K, Miura Y, Satake M (2019) Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view epidemiological research group on viral hepatitis and its long term course ministry of health labour and welfare of Japan. Hepatol Res 49(9):990–1002CrossRef Tanaka J, Akita T, Ko K, Miura Y, Satake M (2019) Countermeasures against viral hepatitis B and C in Japan: an epidemiological point of view epidemiological research group on viral hepatitis and its long term course ministry of health labour and welfare of Japan. Hepatol Res 49(9):990–1002CrossRef
4.
Zurück zum Zitat Yamaguchi S, Kosaka T, Eguchi S (2018) Hepatic resection for hepatocellular carcinoma. Hepatoma Res 4:50CrossRef Yamaguchi S, Kosaka T, Eguchi S (2018) Hepatic resection for hepatocellular carcinoma. Hepatoma Res 4:50CrossRef
5.
Zurück zum Zitat Kobayashi Y, Kiya Y, Sugawara T, Nishioka Y, Hashimoto M, Shindoh J (2019) Expanded Makuuchi’s criteria using estimated indocyanine green clearance rate of future liver remnant as a safety limit for maximum extent of liver resection. HPB (Oxford) 21(8):990–997CrossRef Kobayashi Y, Kiya Y, Sugawara T, Nishioka Y, Hashimoto M, Shindoh J (2019) Expanded Makuuchi’s criteria using estimated indocyanine green clearance rate of future liver remnant as a safety limit for maximum extent of liver resection. HPB (Oxford) 21(8):990–997CrossRef
6.
Zurück zum Zitat Hidaka M, Takatsuki M, Soyama A, Tanaka T, Muraoka I, Hara T et al (2012) Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma. Br J Surg 99(9):1284–1289CrossRef Hidaka M, Takatsuki M, Soyama A, Tanaka T, Muraoka I, Hara T et al (2012) Intraoperative portal venous pressure and long-term outcome after curative resection for hepatocellular carcinoma. Br J Surg 99(9):1284–1289CrossRef
7.
Zurück zum Zitat Kamohara Y, Takatsuki M, Hidaka M, Soyama A, Kanematsu T, Eguchi S (2011) 99mTc-Galactosylsialyl albumin (GSA) scintigram adjusts hepatic resection range in ICG based estimation. Hepatogastroenterology 58(112):2058–2061PubMed Kamohara Y, Takatsuki M, Hidaka M, Soyama A, Kanematsu T, Eguchi S (2011) 99mTc-Galactosylsialyl albumin (GSA) scintigram adjusts hepatic resection range in ICG based estimation. Hepatogastroenterology 58(112):2058–2061PubMed
8.
Zurück zum Zitat Mizoe A, Tomioka T, Inoue K, Azuma T, Fujioka H, Furui J et al (1998) Systematic laparoscopic left lateral segmentectomy of the liver for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 5(2):173–178CrossRef Mizoe A, Tomioka T, Inoue K, Azuma T, Fujioka H, Furui J et al (1998) Systematic laparoscopic left lateral segmentectomy of the liver for hepatocellular carcinoma. J Hepatobiliary Pancreat Surg 5(2):173–178CrossRef
9.
Zurück zum Zitat Yoon YI, Kim KH, Kang SH, Kim WJ, Shin MH, Lee SK et al (2017) Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 265(5):856–863CrossRef Yoon YI, Kim KH, Kang SH, Kim WJ, Shin MH, Lee SK et al (2017) Pure laparoscopic versus open right hepatectomy for hepatocellular carcinoma in patients with cirrhosis: a propensity score matched analysis. Ann Surg 265(5):856–863CrossRef
10.
Zurück zum Zitat Soyama A, Takatsuki M, Adachi T, Kitasato A, Torashima Y, Natsuda K et al (2014) A hybrid method of laparoscopic-assisted open liver resection through a short upper midline laparotomy can be applied for all types of hepatectomies. Surg Endosc 28(1):203–211CrossRef Soyama A, Takatsuki M, Adachi T, Kitasato A, Torashima Y, Natsuda K et al (2014) A hybrid method of laparoscopic-assisted open liver resection through a short upper midline laparotomy can be applied for all types of hepatectomies. Surg Endosc 28(1):203–211CrossRef
11.
Zurück zum Zitat EASL clinical practice guidelines (2018) Management of hepatocellular carcinoma. J Hepatology 69:182–236 EASL clinical practice guidelines (2018) Management of hepatocellular carcinoma. J Hepatology 69:182–236
12.
Zurück zum Zitat Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I et al (2010) Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 34(5):1034–1038CrossRef Eguchi S, Takatsuki M, Hidaka M, Soyama A, Tomonaga T, Muraoka I et al (2010) Predictor for histological microvascular invasion of hepatocellular carcinoma: a lesson from 229 consecutive cases of curative liver resection. World J Surg 34(5):1034–1038CrossRef
13.
Zurück zum Zitat Eguchi S, Soyama A, Hara T, Natsuda K, Okada S, Hamada T et al (2018) Standardized hybrid living donor hemihepatectomy in adult-to-adult living donor liver transplantation. Liver Transpl 24(3):363–368CrossRef Eguchi S, Soyama A, Hara T, Natsuda K, Okada S, Hamada T et al (2018) Standardized hybrid living donor hemihepatectomy in adult-to-adult living donor liver transplantation. Liver Transpl 24(3):363–368CrossRef
14.
Zurück zum Zitat Eguchi S, Kanematsu T, Arii S, Okasaki M, Okita K, Omata M et al (2008) Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 143(4):469–475CrossRef Eguchi S, Kanematsu T, Arii S, Okasaki M, Okita K, Omata M et al (2008) Comparison of the outcomes between an anatomical subsegmentectomy and a non-anatomical minor hepatectomy for single hepatocellular carcinomas based on a Japanese nationwide survey. Surgery 143(4):469–475CrossRef
15.
Zurück zum Zitat Sangiovanni A, Colombo M (2016) Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 36(Suppl 1):124–129CrossRef Sangiovanni A, Colombo M (2016) Treatment of hepatocellular carcinoma: beyond international guidelines. Liver Int 36(Suppl 1):124–129CrossRef
16.
Zurück zum Zitat Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699CrossRef Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334(11):693–699CrossRef
17.
Zurück zum Zitat Eguchi S, Matsumoto S, Hamasaki K, Takatsuki M, Hidaka M, Tajima Y et al (2008) Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection. Hepatobiliary Pancreat Surg 15(6):627–633CrossRef Eguchi S, Matsumoto S, Hamasaki K, Takatsuki M, Hidaka M, Tajima Y et al (2008) Re-evaluation of lipiodolized transarterial chemoembolization therapy for intrahepatic recurrence of hepatocellular carcinoma after curative liver resection. Hepatobiliary Pancreat Surg 15(6):627–633CrossRef
18.
Zurück zum Zitat Hiraoka A, Michitaka K, Kumada T, Izumi N, KadoyaKokuda MN et al (2019) Prediction of prognosis of intermediate-stage HCC patients: validation of the tumor marker score in a nationwide database in Japan. Liver Cancer 8(5):403–411CrossRef Hiraoka A, Michitaka K, Kumada T, Izumi N, KadoyaKokuda MN et al (2019) Prediction of prognosis of intermediate-stage HCC patients: validation of the tumor marker score in a nationwide database in Japan. Liver Cancer 8(5):403–411CrossRef
19.
Zurück zum Zitat Terashima T, Yamashita T, Takata N, Toyama T, Shimakami T, Takatori H et al (2020) Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 19:871–884CrossRef Terashima T, Yamashita T, Takata N, Toyama T, Shimakami T, Takatori H et al (2020) Comparative analysis of liver functional reserve during lenvatinib and sorafenib for advanced hepatocellular carcinoma. Hepatol Res. 19:871–884CrossRef
Metadaten
Titel
Changes in the Role and Mode of Liver Resection for Hepatocellular Carcinoma Over 20 Years: A Single-Center Analysis
verfasst von
Susumu Eguchi
Masaaki Hidaka
Tota Kugiyama
Akihiko Soyama
Takanobu Hara
Kantoku Nagakawa
Tomohiko Adachi
Takayuki Tanaka
Tomoko Yoshimoto
Takashi Hamada
Hajime Matsushima
Sinichiro Ito
Kengo Kanetaka
Publikationsdatum
25.01.2021
Verlag
Springer International Publishing
Erschienen in
World Journal of Surgery / Ausgabe 4/2021
Print ISSN: 0364-2313
Elektronische ISSN: 1432-2323
DOI
https://doi.org/10.1007/s00268-020-05914-3

Weitere Artikel der Ausgabe 4/2021

World Journal of Surgery 4/2021 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.